Additional Effects of Triamcinolone to Hyaluronic Acid on Knee Osteoarthritis

Additional Therapeutic Effects of Triamcinolone to Hyaluronic Acid on Knee Osteoarthritis: A Double Blind, Randomized-controlled Clinical Trial

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02949466

Enrollment

Registered

2016-10-31

Start date

2016-10-31

Completion date

2017-07-31

Last updated

2016-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Performance, Physical Activity

Keywords

knee osteoarthritis, triamcinolone, therapeutic effects

Brief summary

Using a double-blind, randomized controlled design to investigate the additional therapeutic effects of 3 times of combined triamcinolone and hyaluronic acid injections to 3 times of hyaluronic acid injections to patients with knee osteoarthritis.

Detailed description

A total of 56 patients will be enrolled and randomized into two groups, including 3 times of triamcinolone combined hyaluronic acid injections group and 3 times of hyaluronic acid injections group. The triamcinolone combined hyaluronic acid injections group will receive 3 times of triamcinolone combined hyaluronic acid injection per week in three weeks; the hyaluronic acid group will receive hyaluronic acid injection in three weeks. Physical activities and functional performance will be evaluated at before injection, at after one week, one month, three months, and six months of completion of 3 times of injections.

Interventions

DRUGTriamcinolone

compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis

DEVICEHyaluronic acid

compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* knee osteoarthritis with Kellgren/Lawrence grade II or III

Exclusion criteria

* who have neurological deficit, such as stroke who have implant in knee

Design outcomes

Primary

Measure	Time frame	Description
Functional performance assessed with the Western Ontario and McMaster Universities Osteoarthritis Index	changes from baseline to at after one week, one month, three months, and six months of completion of injections	Western Ontario and McMaster Universities Osteoarthritis Index

Secondary

Measure	Time frame	Description
10 meter walk test	changes from baseline to at after one week, one month, three months, and six months of completion of injections	10 meter walk as fast as possible
Quality of life assessed with the Knee Injury and Osteoarthritis Outcome Score	changes from baseline to at after one week, one month, three months, and six months of completion of injections	Knee Injury and Osteoarthritis Outcome Score
5 times rapid chair rising test	changes from baseline to at after one week, one month, three months, and six months of completion of injections	rapid chair rising for 5 times as fast as possible

Countries

Taiwan

Contacts

Primary ContactRu-Lan Hsieh, MD

M001052@ms.skh.org.tw886-2-28332211

Backup ContactRu-Lan Hsieh, MD

rulan@tmu.edu.tw886-2-28332211

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026